Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia

Ryan K. Shields; M. Hong Nguyen; Liang Chen; Ellen G. Press; Brian A. Potoski; Rachel V. Marini; Yohei Doi; Barry N. Kreiswirth; Cornelius J. Clancy

doi:10.1128/AAC.00883-17

Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia

Ryan K. Shields, M. Hong Nguyen, Liang Chen, Ellen G. Press, Brian A. Potoski, Rachel V. Marini, Yohei Doi, Barry N. Kreiswirth, Cornelius J. Clancy

Research output: Contribution to journal › Article › peer-review

381 Citations (Scopus)

Abstract

There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumoniae bacteremia was associated with higher rates of clinical success (P = 0.006) and survival (P = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced K. pneumoniae carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity (P = 0.002).

Original language	English
Article number	e00883
Journal	Antimicrobial agents and chemotherapy
Volume	61
Issue number	8
DOIs	https://doi.org/10.1128/AAC.00883-17
Publication status	Published - 08-2017
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/AAC.00883-17

Cite this

@article{8c1dfcfc11444e4e95cc15caa493adea,

title = "Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia",

abstract = "There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumoniae bacteremia was associated with higher rates of clinical success (P = 0.006) and survival (P = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced K. pneumoniae carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity (P = 0.002).",

author = "Shields, {Ryan K.} and Nguyen, {M. Hong} and Liang Chen and Press, {Ellen G.} and Potoski, {Brian A.} and Marini, {Rachel V.} and Yohei Doi and Kreiswirth, {Barry N.} and Clancy, {Cornelius J.}",

year = "2017",

month = aug,

doi = "10.1128/AAC.00883-17",

language = "English",

volume = "61",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "8",

}

TY - JOUR

T1 - Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia

AU - Shields, Ryan K.

AU - Nguyen, M. Hong

AU - Chen, Liang

AU - Press, Ellen G.

AU - Potoski, Brian A.

AU - Marini, Rachel V.

AU - Doi, Yohei

AU - Kreiswirth, Barry N.

AU - Clancy, Cornelius J.

PY - 2017/8

Y1 - 2017/8

N2 - There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumoniae bacteremia was associated with higher rates of clinical success (P = 0.006) and survival (P = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced K. pneumoniae carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity (P = 0.002).

AB - There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumoniae bacteremia was associated with higher rates of clinical success (P = 0.006) and survival (P = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced K. pneumoniae carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity (P = 0.002).

UR - http://www.scopus.com/inward/record.url?scp=85026380424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026380424&partnerID=8YFLogxK

U2 - 10.1128/AAC.00883-17

DO - 10.1128/AAC.00883-17

M3 - Article

C2 - 28559250

AN - SCOPUS:85026380424

SN - 0066-4804

VL - 61

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 8

M1 - e00883

ER -

Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this